Effects of olanzapine and clozapine on radial maze performance in naive and MK-801-treated mice

Arzneimittel-Forschung/Drug Research

Volumn 62, Issue 1, 2012, Pages 4-8

  Mutlu, O ^a   Celikyurt, I K ^a   Ulak, G ^a   Tanyeri, P ^a   Akar, F Y ^a   Erden, F ^a  

^a KOCAELI UNIVERSITY   (Turkey)

Author keywords

atypical antipsychotics; mice; MK 801; radial arm maze task; spatial memory

Indexed keywords

CLOZAPINE; DIZOCILPINE; OLANZAPINE; AMINO ACID RECEPTOR BLOCKING AGENT; BENZODIAZEPINE DERIVATIVE; DIZOCILPINE MALEATE; NEUROLEPTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BAGG ALBINO MOUSE; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFECT; MALE; MAZE TEST; MEMORY DISORDER; NONHUMAN; SCHIZOPHRENIA; SPATIAL MEMORY; TASK PERFORMANCE; WORKING MEMORY; ANIMAL; MOUSE;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLOZAPINE; DIZOCILPINE MALEATE; EXCITATORY AMINO ACID ANTAGONISTS; MALE; MAZE LEARNING; MICE; MICE, INBRED BALB C;

EID: 84858725938     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1291360     Document Type: Article

References (45)

1. Green M F, Kern R S, Braff D L et al. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuffo"? Schizophr Bull: 2000; 26 119 136 (Pubitemid 30317696)
2. Green M F, Nuechterlein K H, Gold J M et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry: 2004; 56 301 307 (Pubitemid 39164514)
3. Harvey P D, Green M F, Keefe R S et al. Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness. J Clin Psychiatry: 2004; 65 361 372
4. Didriksen M, Skarsfeldt T, Arnt J. Reversal of PCP-induced learning and memory deficits in the Morris' water maze by sertindole and other antipsychotics. Psychopharmacology: 2007; 193 225 233 (Pubitemid 47025022)
5. Mortimer A M. Cognitive function in schizophrenia - do neuroleptics make a difference? Pharmacol Biochem Behav: 1997; 56 789 795 (Pubitemid 27189765)
6. Cleghorn J M, Kaplan R D, Szechtman B et al. Neuroleptic drug effects on cognitive function in schizophrenia. Schizophr Res: 1990; 3 211 219 (Pubitemid 20157298)
7. Fulton B, Goa K L. Olanzapine, a review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs: 1997; 53 281 298 (Pubitemid 27073117)
8. Kane J M, Tamminga C A. Sertindole (serdolect): preclinical and clinical findings of a new atypical antipsychotic. Exp Opin Invest Drugs: 1997; 6 1729 1741 (Pubitemid 27488037)
9. Krystal J H, Karper L P, Seibyl J P et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry: 1994; 51 199 214 (Pubitemid 24081509)
10. Jafari-Sabet M. NMDA receptor antagonists antagonize the facilitatory effects of post-training intra-basolateral amygdala NMDA and physostigmine on passive avoidance learning. Eur J Pharmacol: 2006; 529 122 128 (Pubitemid 43005293)
11. Harvey P D, Kefe R S. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry: 2001; 158 176 184 (Pubitemid 32116511)
12. Goldberg T E, Greenberg R D, Griffin S J et al. The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br J Psychiatry: 1993; 162 43 48 (Pubitemid 23017012)
13. Meltzer H Y, McGurk S R. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull: 1999; 25 233 255 (Pubitemid 29272503)
14. Hoff A L, Faustman W O, Wieneke M et al. The effect of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients. Neuropsychopharmacology: 1996; 15 361 369 (Pubitemid 26342919)
15. Beuzen A, Belzung C, Roullet P. Drug effects in a radial maze designed for dissociation of cues used by mice. Pharmacol Biochem Behav: 1994; 48 23 29
16. Belzung C, Le Guisquet A M, Griebel G. b-CCT, a selective BZ-v receptor antagonist, blocks the anti-anxiety but not the amnesic action of chlordiazepoxide in mice. Behav Pharmacol: 2000; 11 125 131 (Pubitemid 30315847)
17. Didriksen M, Kreilgaard M, Arnt J. Sertindole, in contrast to clozapine and olanzapine, does not disrupt water maze performance after acute or chronic treatment. Eur J Pharmacol: 2006; 542 108 115 (Pubitemid 44066366)
18. Skarsfeldt T. Differential effect of antipsychotics on place navigation of rats in the Morris water maze. Psychopharmacology: 1996; 124 126 133
19. Nagai T, Kamei H, Dohniwa M et al. Involvement of hippocampal extracellular signal-regulated kinase 1/2 in spatial working memory in rats. Neuroreport: 2006; 17 1453 1457 (Pubitemid 44299393)
20. Suzuki S, Augerinos G, Black A H. Stimulus control of spatial behavior on the eight-arm maze in rats. Learn Motiv: 1980; 11 1 18
21. Zou L B, Yamada K, Nabeshima T. Sigma receptor ligands (+)- SKF10,047 and SA4503 improve dizocilpine-induced spatial memory deficits in rats. Eur J Pharmacol: 1998; 355 1 10 (Pubitemid 28401499)
22. Lee M A, Jayathilake K, Meltzer H Y. A comparison of effect of clozapine with typical neuroleptics on cognitive function in neuroleptic-responsive schizophrenia. Schizoph Res: 1999; 37 1 12
23. Jentsch J D, Tran A, Le D et al. Sub-chronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat. Neuropsychopharmacology: 1997; 17 92 99
24. Didriksen M. Effects of antipsychotics on cognitive behaviour in rats using the delayed non-match to position paradigm. Eur J Pharmacol: 1995; 281 241 250
25. Enomoto T, Ishibashi T, Tokuda K et al. Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in rats. Behav Brain Res: 2008; 186 197 207 (Pubitemid 350122756)
26. Bymaster F, Perry K W, Nelson D L et al. Olanzapine: a basic science update. Br J Psychiatry Suppl: 1999; 37 36 40 (Pubitemid 29089310)
27. He H, Richardson J S. A pharmacological, pharmacokinetic and clinical overview of risperidone, a new antipsychotic that blocks serotonin 5-HT2 and dopamine D2 receptors. Int Clin Psychopharmacol: 1995; 10 19 30
28. Stephenson C M, Pilowsky L S. Psychological of olanzapine. A review. Br J Psychiatry: 1999; 38 52 58
29. Schotte A, Janssen P F, Gommeren W et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology: 1996; 124 57 73 (Pubitemid 26112775)
30. Terry A V Jr, Buccafusco J J, Bartoszyk G D. Selective serotonin 5-HT2A receptor antagonist EMD 281014 improves delayed matching performance in young and aged rhesus monkeys. Psychopharmacology (Berl): 2005; 179 725 732 (Pubitemid 40767893)
31. Winstanley C A, Chudasama Y, Dalley J W et al. Intra-prefrontal 8-OH-DPAT and M100907 improve visuospatial attention and decrease impulsivity on the five-choice serial reaction time task in rats. Psychopharmacology (Berl): 2003; 167 304 314 (Pubitemid 36712978)
32. Li X M, Perry K W, Wong D T et al. Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum. Psychopharmacology: 1998; 136 153 161 (Pubitemid 28137955)
33. Bymaster F P, Falcone J F, Bauzon D et al. Potent antagonism of 5-HT(3) and 5-HT(6) receptors by olanzapine. Eur J Pharmacol: 2001; 430 341 349 (Pubitemid 33050060)
34. Rogers D C, Robinson T L, Quilter C A et al. Cognitive enhancement effects of the selective 5-HT6 antagonist SB-271046. Br J Pharmacol: 1999; 127 22
35. Dawson L A, Huy O, Nguyen B S et al. The 5-HT6 receptor antagonist SB- 271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus. Neuropsychopharmacology: 2001; 25 662 668 (Pubitemid 32995948)
36. Okamura N, Yanai K, Higuchi M et al. Functional neuroimaging of cognition impaired by a classical antihistamine, D-chlorpheniramine. Br J Pharmacol: 2000; 129 115 123 (Pubitemid 30072677)
37. Tashiro M, Mochizuki H, Iwabuchi K et al. Roles of histamine in regulation of arousal and cognition: functional neuroimaging of histamine H1 receptors in human brain. Life Sci: 2002; 72 409 414 (Pubitemid 35452554)
38. Altar C A, Wasley A M, Neale R F et al. Typical and atypical antipsychotic occupancy of D2 and S2 receptors: an autoradiographic analysis in rat brain. Brain Res Bull: 1986; 16 517 525 (Pubitemid 16038474)
39. Lipska B K, Weinberger D R. To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology: 2000; 23 223 239 (Pubitemid 30609657)
40. Abdul-Monim Z, Reynolds G P, Neill J C. The atypical antipsychotic ziprasidone, but not haloperidol, improves phencyclidine-induced cognitive deficits in a reversal learning task in the rat. J Psychopharmacol: 2003; 17 57 65 (Pubitemid 36373141)
41. Cartmell J, Monn J A, Schoepp D D. Attenuation of specific PCP-evoked behaviors by the potent mGlu2/3 receptor agonist, LY379268 and comparison with the atypical antipsychotic, clozapine. Psychopharmacology (Berl): 2000; 148 423 429 (Pubitemid 30169761)
42. Gleason S D, Shannon H E. Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice. Psychopharmacology: 1997; 129 79 84 (Pubitemid 27037454)
43. Mathé J M, Nomikos G G, Hildebrand B E et al. Prazosin inhibits MK-801-induced hyperlocomotion and dopamine release in the nucleus accumbens. Eur J Pharmacol: 1996; 309 1 11 (Pubitemid 26253010)
44. Mutlu O, Ulak G, Celikyurt I K et al. Effects of olanzapine, sertindole and clozapine on learning and memory in the Morris water maze test in naive and MK-801-treated mice. Pharmacol Biochem Behavior: 2011; 98 398 404
45. Mutlu O, Ulak G, Celikyurt I K et al. Effects of olanzapine, sertindole and clozapine on MK-801 induced visual memory deficits in mice. Pharmacol Biochem Behavior: 2011; 99 557 565